Niagen Bioscience, Inc.
NAGE Nasdaq
SEC CIK 1386570
Follow Niagen Bioscience
Weekly email: filings, results
Revenue, last quarter
$27.2M
−20% vs same quarter last year
Net income
−$1.2M
−125.6% vs same quarter last year
EPS, diluted
−$0.01
−120% vs same quarter last year
Operating cash flow
$2.6M
−28.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $129.4M | $17.4M |
| FY24 | $99.6M | $8.6M |
| FY23 | $83.6M | −$4.9M |
| FY22 | $72.1M | −$16.5M |
| FY21 | $67.4M | −$27.1M |
| FY20 | $59.3M | −$19.9M |
| FY19 | $46.3M | −$32.1M |
| FY18 | $31.6M | −$33.3M |
| FY17 | $21.2M | −$11.4M |
| FY16 | $21.7M | −$2.9M |
| FY15 | $17.9M | −$2.8M |
| FY14 | $15.3M | −$5.4M |
| FY13 | $10.2M | −$4.4M |
| FY12 | $11.6M | −$11.7M |
| FY11 | $8.1M | −$7.9M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 64.3% | 12.6% | 13.4% |
| FY24 | 61.8% | 7.8% | 8.6% |
| FY23 | 60.8% | −6.7% | −5.9% |
| FY22 | 59.4% | −25.9% | −23% |
| FY21 | 61.5% | −40.1% | −40.2% |
| FY20 | 59.5% | −33.5% | −33.6% |
| FY19 | 55.7% | −67.6% | −69.4% |
| FY18 | 50.9% | −105.1% | −105.6% |
| FY17 | 49.4% | −77.2% | −53.7% |
| FY16 | 48% | −13.4% | −13.5% |
| FY15 | 42.1% | −11.6% | −15.5% |
| FY14 | 34.8% | −34.2% | −35.2% |
| FY13 | 30.8% | −43.2% | −43.5% |
| FY12 | 19.6% | −100.2% | −100.4% |
| FY11 | 30.5% | −96.9% | −97.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | −$21.2M |
| FY18 | −$22.2M |
| FY17 | −$11M |
| FY16 | −$4.4M |
| FY15 | −$2.6M |
| FY14 | −$2.7M |
| FY13 | −$4M |
| FY12 | −$10.1M |
| FY11 | −$4.2M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $251K |
| FY24 | $0 |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | $404K |
| FY17 | $0 |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | $8.2K |
| FY11 | - |
- Niagen Bioscience
- Healthcare median
Show the numbers
| Year | Niagen Bioscience | Healthcare median |
|---|---|---|
| FY25 | 13.4% | −30.6% |
| FY24 | 8.6% | −47% |
| FY23 | −5.9% | −58% |
| FY22 | −23% | −80.4% |
| FY21 | −40.2% | −71.8% |
| FY20 | −33.6% | −62.2% |
| FY19 | −69.4% | −46.2% |
| FY18 | −105.6% | −49.6% |
| FY17 | −53.7% | −45.9% |
| FY16 | −13.5% | −36% |
| FY15 | −15.5% | −37.8% |
| FY14 | −35.2% | −35.5% |
| FY13 | −43.5% | −37.1% |
| FY12 | −100.4% | −29.1% |
| FY11 | −97.3% | −27.9% |